JP6774690B1 - Antiviral alloy - Google Patents
Antiviral alloy Download PDFInfo
- Publication number
- JP6774690B1 JP6774690B1 JP2019165563A JP2019165563A JP6774690B1 JP 6774690 B1 JP6774690 B1 JP 6774690B1 JP 2019165563 A JP2019165563 A JP 2019165563A JP 2019165563 A JP2019165563 A JP 2019165563A JP 6774690 B1 JP6774690 B1 JP 6774690B1
- Authority
- JP
- Japan
- Prior art keywords
- weight
- tin
- silver
- gold
- alloy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C5/00—Alloys based on noble metals
- C22C5/06—Alloys based on silver
Abstract
【課題】抗ウイルス性を有する合金を提供する。【解決手段】抗ウイルス性を有する合金であって、２．５重量％から１０．０重量％の錫（Ｓｎ）と、０．０１重量％から１．０重量％の金（Ａｕ）とが含まれ、残部が銀（Ａｇ）で構成される。【選択図】なしPROBLEM TO BE SOLVED: To provide an alloy having antiviral property. An alloy having antiviral properties, consisting of 2.5% by weight to 10.0% by weight of tin (Sn) and 0.01% by weight to 1.0% by weight of gold (Au). Included, the balance is composed of silver (Ag). [Selection diagram] None
Description
従来、合金は、優れた加工特性を有するため、装飾品や金属材料に使用されてきた。例えば、銀−銅合金粉末と有機系バインダとを含有した装飾用の銀含有可塑性組成物としても使用されている（例えば、特許文献１）。
また、銀が含有された合金や化合物は、抗菌性や抗ウイルス性を有するため、医療の現場で使用される金属材料や衛生用品にも使用されている（例えば、特許文献２、及び特許文献３）。
Traditionally, alloys have been used in ornaments and metal materials due to their excellent processing properties. For example, it is also used as a decorative silver-containing plastic composition containing a silver-copper alloy powder and an organic binder (for example, Patent Document 1).
In addition, since silver-containing alloys and compounds have antibacterial and antiviral properties, they are also used in metal materials and sanitary products used in the medical field (for example, Patent Document 2 and Patent Documents). 3).
これまで開示されている抗ウイルス性を有する銀合金は、含有させる金属の種類が多く、
例えば、ニッケル（Ｎｉ）は、特に強い金属アレルギーを引き起こす原因となり、鉛（Ｐｂ）は、有害物質であるため、人の肌に直接触れる用途に使用することは困難である。
そのため、人の肌に触れる場所や物に適用できる、汎用性の高い抗ウイルス性を有する合金が求められている。
The silver alloys having antiviral properties disclosed so far contain many types of metals.
For example, nickel (Ni) causes a particularly strong metal allergy, and lead (Pb) is a toxic substance, so it is difficult to use it for applications that come into direct contact with human skin.
Therefore, there is a demand for a highly versatile antiviral alloy that can be applied to places and objects that come into contact with human skin.
そこで、本発明は、抗ウイルス性を有する合金を提供することを目的とする。 Therefore, an object of the present invention is to provide an alloy having antiviral properties.
本発明の合金は、抗ウイルス性を有し、２．５重量％から１０．０重量％の錫（Ｓｎ）と、０．０１重量％から１．０重量％の金（Ａｕ）とが含まれ、残部が銀（Ａｇ）で構成されることを特徴とする。 The alloy of the present invention is antiviral and contains 2.5% to 10.0% by weight tin (Sn) and 0.01% to 1.0% by weight gold (Au). It is characterized in that the balance is composed of silver (Ag).
本発明の合金は、錫（Ｓｎ）が３．９５重量％以上含まれていることが好ましい。 The alloy of the present invention preferably contains tin (Sn) in an amount of 3.95% by weight or more.
本発明に係る合金は、２．５重量％から１０．０重量％の錫（Ｓｎ）と、０．０１重量％から１．０重量％の金（Ａｕ）とが含まれ、残部が銀（Ａｇ）で構成されている。
上記の濃度で金属が含有された合金は、純銀（銀１００％）よりも高い抗ウイルス性を示すと共に、加工性にも優れ、極めて実用的価値が高い。そのため、医療分野や食品分野などの抗ウイルス性を強く求められる材料に応用することができる。
The alloy according to the present invention contains 2.5% by weight to 10.0% by weight of tin (Sn) and 0.01% by weight to 1.0% by weight of gold (Au), with the balance being silver (s). It is composed of Ag).
Alloys containing metals at the above concentrations exhibit higher antiviral properties than pure silver (100% silver), are also excellent in processability, and have extremely high practical value. Therefore, it can be applied to materials strongly required to have antiviral properties such as medical fields and food fields.
本実施形態に係る合金について、説明する。
本実施形態に係る合金は、銀（Ａｇ）、錫（Ｓｎ）、及び金（Ａｕ）を含んでいる。これらの合金は、錫（Ｓｎ）が２．５重量％から１０．０重量％、金（Ａｕ）が０．０１重量％から１．０重量％がそれぞれ含まれ、残部が銀（Ａｇ）で構成されている。
The alloy according to this embodiment will be described.
The alloy according to this embodiment contains silver (Ag), tin (Sn), and gold (Au). These alloys contain 2.5% to 10.0% by weight of tin (Sn), 0.01% to 1.0% by weight of gold (Au), and the balance is silver (Ag). It is configured.
本実施形態では、表１に示した濃度で合金を作製し（実施例１から実施例７、及び比較例１から比較例１４）、これらの合金の抗ウイルス性を調べた。 In this embodiment, alloys were prepared at the concentrations shown in Table 1 (Examples 1 to 7 and Comparative Examples 1 to 14), and the antiviral properties of these alloys were examined.
実施例１から実施例７の合金の組成は、以下の通りである。
［実施例１］：銀（Ａｇ）（９７．０重量％）、錫（Ｓｎ）（２．９０重量％）、金（Ａｕ）（０．１０重量％）
［実施例２］：銀（Ａｇ）（９５．０５重量％）、錫（Ｓｎ）（３．９５重量％）、金（Ａｕ）（１．００重量％）
［実施例３］：銀（Ａｇ）（９５．５０重量％）、錫（Ｓｎ）（３．９５重量％）、金（Ａｕ）（０．５５重量％）
［実施例４］：銀（Ａｇ）（９５．９５重量％）、錫（Ｓｎ）（３．９５重量％）、金（Ａｕ）（０．１０重量％）
［実施例５］：銀（Ａｇ）（９６．０４重量％）、錫（Ｓｎ）（３．９５重量％）、金（Ａｕ）（０．０１重量％）
［実施例６］：銀（Ａｇ）（９２．５０重量％）、錫（Ｓｎ）（７．４０重量％）、金（Ａｕ）（０．１０重量％）
［実施例７］：銀（Ａｇ）（９０．００重量％）、錫（Ｓｎ）（９．９０重量％）、金（Ａｕ）（０．１０重量％）
The composition of the alloys of Examples 1 to 7 is as follows.
[Example 1]: Silver (Ag) (97.0% by weight), Tin (Sn) (2.90% by weight), Gold (Au) (0.10% by weight)
[Example 2]: Silver (Ag) (95.05% by weight), Tin (Sn) (3.95% by weight), Gold (Au) (1.00% by weight)
[Example 3]: Silver (Ag) (95.50% by weight), Tin (Sn) (3.95% by weight), Gold (Au) (0.55% by weight)
[Example 4]: Silver (Ag) (95.95% by weight), Tin (Sn) (3.95% by weight), Gold (Au) (0.10% by weight)
[Example 5]: Silver (Ag) (96.04% by weight), Tin (Sn) (3.95% by weight), Gold (Au) (0.01% by weight)
[Example 6]: Silver (Ag) (92.50% by weight), Tin (Sn) (7.40% by weight), Gold (Au) (0.10% by weight)
[Example 7]: Silver (Ag) (90.00% by weight), Tin (Sn) (9.90% by weight), Gold (Au) (0.10% by weight)
比較例１から比較例１４として、以下の合金を作製した。比較例８から比較例１１、比較例１３、比較例１４は、金（Ａｕ）を含まない合金、比較例１２から比較例１４では、錫（Ｓｎ）を含まない合金とした。そして、比較例９及び比較例１３は、ゲルマニウム（Ｇｅ）、比較例１０及び比較例１４では銅（Ｃｕ）をそれぞれ含有させた合金とした。 The following alloys were produced as Comparative Examples 1 to 14. Comparative Examples 8 to 11, Comparative Example 13, and Comparative Example 14 were alloys containing no gold (Au), and Comparative Examples 12 to 14 were alloys containing no tin (Sn). Then, Comparative Example 9 and Comparative Example 13 were alloys containing germanium (Ge), and Comparative Example 10 and Comparative Example 14 were alloys containing copper (Cu), respectively.
［比較例１］：銀（Ａｇ）（９６．０４９重量％）、錫（Ｓｎ）（３．９５重量％）、金（Ａｕ）（０．００１重量％）
［比較例２］：銀（Ａｇ）（９９．０重量％）、錫（Ｓｎ）（０．９０重量％）、金（Ａｕ）（０．１０重量％）
［比較例３］：銀（Ａｇ）（９９．５０重量％）、錫（Ｓｎ）（０．４０重量％）、金（Ａｕ）（０．１０重量％）
［比較例４］：銀（Ａｇ）（８０．００重量％）、錫（Ｓｎ）（１９．９０重量％）、金（Ａｕ）（０．１０重量％）
［比較例５］：銀（Ａｇ）（５０．００重量％）、錫（Ｓｎ）（４９．９０重量％）、金（Ａｕ）（０．１０重量％）
［比較例６］：銀（Ａｇ）（９．９０重量％）、錫（Ｓｎ）（９０．００重量％）、金（Ａｕ）（０．１０重量％）
［比較例７］：銀（Ａｇ）（０．４０重量％）、錫（Ｓｎ）（９９．５０重量％）、金（Ａｕ）（０．１０重量％）
［比較例８］：銀（Ａｇ）（９６．０５重量％）、錫（Ｓｎ）（３．９５重量％）
［比較例９］：銀（Ａｇ）（９５．５０重量％）、錫（Ｓｎ）（３．９５重量％）、ゲルマニウム（Ｇｅ）（０．５５重量％）
［比較例１０］：銀（Ａｇ）（９５．５０重量％）、錫（Ｓｎ）（３．９５重量％）、銅（Ｃｕ）（０．５５重量％）
［比較例１１］：銀（Ａｇ）（９５．５０重量％）、錫（Ｓｎ）（４．５０重量％）
［比較例１２］：銀（Ａｇ）（９５．５０重量％）、金（Ａｕ）（４．５０重量％）
［比較例１３］：銀（Ａｇ）（９５．５０重量％）、ゲルマニウム（Ｇｅ）（４．５０重量％）［比較例１４］：銀（Ａｇ）（９５．５０重量％）、銅（Ｃｕ）（４．５０重量％）
［比較例１５］：銀（Ａｇ）（１００重量％）
[Comparative Example 1]: Silver (Ag) (96.049% by weight), Tin (Sn) (3.95% by weight), Gold (Au) (0.001% by weight)
[Comparative Example 2]: Silver (Ag) (99.0% by weight), Tin (Sn) (0.90% by weight), Gold (Au) (0.10% by weight)
[Comparative Example 3]: Silver (Ag) (99.50% by weight), Tin (Sn) (0.40% by weight), Gold (Au) (0.10% by weight)
[Comparative Example 4]: Silver (Ag) (80.00% by weight), Tin (Sn) (19.90% by weight), Gold (Au) (0.10% by weight)
[Comparative Example 5]: Silver (Ag) (50.00% by weight), Tin (Sn) (49.90% by weight), Gold (Au) (0.10% by weight)
[Comparative Example 6]: Silver (Ag) (9.90% by weight), Tin (Sn) (90.00% by weight), Gold (Au) (0.10% by weight)
[Comparative Example 7]: Silver (Ag) (0.40% by weight), Tin (Sn) (99.50% by weight), Gold (Au) (0.10% by weight)
[Comparative Example 8]: Silver (Ag) (96.05% by weight), Tin (Sn) (3.95% by weight)
[Comparative Example 9]: Silver (Ag) (95.50% by weight), Tin (Sn) (3.95% by weight), Germanium (Ge) (0.55% by weight)
[Comparative Example 10]: Silver (Ag) (95.50% by weight), Tin (Sn) (3.95% by weight), Copper (Cu) (0.55% by weight)
[Comparative Example 11]: Silver (Ag) (95.50% by weight), Tin (Sn) (4.50% by weight)
[Comparative Example 12]: Silver (Ag) (95.50% by weight), Gold (Au) (4.50% by weight)
[Comparative Example 13]: Silver (Ag) (95.50% by weight), Germanium (Ge) (4.50% by weight) [Comparative Example 14]: Silver (Ag) (95.50% by weight), Copper (Cu) ) (4.50% by weight)
[Comparative Example 15]: Silver (Ag) (100% by weight)
各合金の抗ウイルス性試験を以下の通り行った。
具体的には、各合金（３５ｍｍ×３５ｍｍ×厚さ１ｍｍ）をバクテリオファージφ６（抗インフルエンザ代替ウイルス）希釈液（１／４ＮＢ）に、室温下で、５分間浸漬させた後、抗ウイルス性を調べた。抗ウイルス性試験は、ＪＩＳ Ｒ１７５６（２０１３（可視光応答型光触媒、抗ウイルス（バクテリオファージ）））を参考に行った。なお、密着フィルムには、ポリプロピレンフィルム（３０ｍｍ×３０ｍｍ）を使用した。
試験後、抗ウイルス活性値を比較することで、評価した。抗ウイルス活性値は以下の式によって計算した。
Ｖ＝Ｕ０−Ａｔ
Ｖ：抗ウイルス活性値
Ｕ０：接種量あたりのバクテリオファージの感染価の対数値
Ａｔ：試料の反応後の感染価の対数値
The antiviral test of each alloy was performed as follows.
Specifically, each alloy (35 mm × 35 mm × thickness 1 mm) is immersed in a bacteriophage φ6 (anti-influenza substitute virus) diluted solution (1/4 NB) at room temperature for 5 minutes, and then has antiviral properties. Examined. The antiviral test was carried out with reference to JIS R1756 (2013 (visible light responsive photocatalyst, antiviral (bacteriophage))). A polypropylene film (30 mm × 30 mm) was used as the adhesion film.
After the test, it was evaluated by comparing the antiviral activity values. The antiviral activity value was calculated by the following formula.
V = U 0 -A t
V: Antiviral activity value U 0: infectivity logarithm A t of bacteriophage per inoculum: Infectivity logarithm after reaction of the sample
評価基準は以下の通りとした。
◎：抗ウイルス活性値５．３以上
〇：抗ウイルス活性値２．５以上５．３未満
△：抗ウイルス活性値１．０以上２．５未満
×：抗ウイルス活性値１．０未満
The evaluation criteria are as follows.
⊚: Antiviral activity value 5.3 or more 〇: Antiviral activity value 2.5 or more and less than 5.3 Δ: Antiviral activity value 1.0 or more and less than 2.5 ×: Antiviral activity value less than 1.0
各合金の抗ウイルス性試験の結果を表１に示した。
実施例２から実施例７に係る合金は、非常に高い抗ウイルス性を示し、実施例１の合金はやや高い抗ウイルス性を示すことがわかった。このことから、これらの合金は、バクテリオファージφ６を不活性化させる特性を有することがわかった。そして、これら実施例１から実施例７の合金は全て、比較例１５（純銀）よりも高い抗ウイルス性を示すことも明らかとなった。
また、実施例１から実施例７に係る合金は、加工性にも優れていることがわかった。
The results of the antiviral test of each alloy are shown in Table 1.
It was found that the alloys of Examples 2 to 7 showed very high antiviral properties, and the alloys of Example 1 showed slightly high antiviral properties. From this, it was found that these alloys have the property of inactivating the bacteriophage φ6. It was also revealed that all of the alloys of Examples 1 to 7 exhibited higher antiviral properties than Comparative Example 15 (pure silver).
Further, it was found that the alloys according to Examples 1 to 7 were also excellent in workability.
まず、錫（Ｓｎ）を含有させた効果について説明する。
実施例１から実施例７と比較例１２（錫（Ｓｎ）不含有）、比較例１３（錫（Ｓｎ）の代わりにゲルマニウム（Ｇｅ）を含有）及び比較例１４（錫（Ｓｎ）の代わりに銅（Ｃｕ）を含有う）の結果を比較すると、錫（Ｓｎ）を含有させた合金が高い抗ウイルス性を有していることがわかった。実施例１から実施例７に係る合金において、錫（Ｓｎ）が３．９５重量％以上含有されていることで、特に高い抗ウイルス性を示すことがわかった。
また、比較例２から比較例７の結果から、錫（Ｓｎ）の濃度が２．５重量％から１０．０重量％の範囲外の合金では、抗ウイルス性が低い、あるいは、所望の形状に加工ができないことがわかった。
First, the effect of containing tin (Sn) will be described.
Examples 1 to 7 and Comparative Example 12 (without tin (Sn)), Comparative Example 13 (containing germanium (Ge) instead of tin (Sn)), and Comparative Example 14 (instead of tin (Sn)). Comparing the results of copper (Cu) contained), it was found that the tin (Sn) -containing alloy has high antiviral properties. It was found that the alloys according to Examples 1 to 7 exhibited particularly high antiviral properties when tin (Sn) was contained in an amount of 3.95% by weight or more.
Further, from the results of Comparative Examples 2 to 7, alloys having a tin (Sn) concentration outside the range of 2.5% by weight to 10.0% by weight have low antiviral properties or have a desired shape. It turned out that it could not be processed.
次に、金（Ａｕ）を含有させた効果について説明する。
実施例２と比較例８（金（Ａｕ）不含有）及び比較例９（金（Ａｕ）の代わりにゲルマニウム（Ｇｅ）を含有）の結果を比較すると、金（Ａｕ）を含有させた合金が高い抗ウイルス性を有していることが明らかである。さらに比較例１（金（Ａｕ）：０．００１重量％）の結果から、金（Ａｕ）を０．１０重量％以上含有させることで、高い抗ウイルス性を付与できると考えられる。ただし、金（Ａｕ）は高価であるため、１．００重量％以下であることが好ましい。
なお、比較例１１（金（Ａｕ）不含有）と比較例１２（錫（Ｓｎ）不含有）の結果から、同じ濃度であれば、金（Ａｕ）を含有させた合金の方が錫（Ｓｎ）を含有させた合金よりも、高い抗ウイルス性を示すことがわかる。
Next, the effect of containing gold (Au) will be described.
Comparing the results of Example 2 with Comparative Example 8 (without gold (Au)) and Comparative Example 9 (containing germanium (Ge) instead of gold (Au)), the alloy containing gold (Au) was found. It is clear that it has high antiviral properties. Further, from the result of Comparative Example 1 (gold (Au): 0.001% by weight), it is considered that high antiviral property can be imparted by containing 0.10% by weight or more of gold (Au). However, since gold (Au) is expensive, it is preferably 1.00% by weight or less.
From the results of Comparative Example 11 (without gold (Au)) and Comparative Example 12 (without tin (Sn)), the alloy containing gold (Au) is more tin (Sn) at the same concentration. It can be seen that it exhibits higher antiviral properties than the alloy containing).
以上の結果から、銀（Ａｇ）−錫（Ｓｎ）−金（Ａｕ）合金とし、錫（Ｓｎ）が２．５重量％から１０．０重量％、金（Ａｕ）が０．０１重量％から１．０重量％がそれぞれ含まれていることで、高い抗ウイルス性を示すことがわかった。さらに、これらの合金は、純銀よりも高い抗ウイルス性を示すことも明らかとなった。 From the above results, a silver (Ag) -tin (Sn) -gold (Au) alloy is used, with tin (Sn) from 2.5% by weight to 10.0% by weight and gold (Au) from 0.01% by weight. It was found that a high antiviral property was exhibited by containing 1.0% by weight of each. Furthermore, it was revealed that these alloys show higher antiviral properties than sterling silver.
また、本実施形態の銀（Ａｇ）−錫（Ｓｎ）−金（Ａｕ）合金は、抗ウイルス性を有することに加え、加工性にも優れているため、医療分野（例えば、ドアハンドル、医療用メス、医療用ピンセット、医療用バット、回診車）、食品分野（例えば、トング、食器、厨房機器）、日用品分野（例えば、つめきり、毛抜き、耳かき）、住宅関連分野（例えば、三角コーナー、排水口、洗面台、シンク）、家電分野（例えば、空気清浄機フィルター、エアコンフィルター、掃除機）、機械設備関連分野（例えば、ボルト、ねじ）、及び畜産関連分野（防鳥ネット、床、壁）に応用することができる。 Further, since the silver (Ag) -tin (Sn) -gold (Au) alloy of the present embodiment has excellent processability in addition to having antiviral properties, it is excellent in the medical field (for example, door handle, medical treatment). Medical scalpels, medical tweezers, medical bats, round-trip cars), food fields (eg tongs, tableware, kitchen equipment), daily necessities fields (eg claws, hair removers, ear cleaners), housing related fields (eg triangular corners, drainage) Mouth, wash basin, sink), household appliances (eg air purifier filter, air conditioner filter, vacuum cleaner), machinery related fields (eg bolts, screws), and livestock related fields (bird nets, floors, walls) Can be applied to.
さらに、本実施形態の銀（Ａｇ）−錫（Ｓｎ）−金（Ａｕ）合金は、例えば、スパッタリング法、真空蒸着法、イオンプレーティング法で使用する薄膜形成用ターゲット材として使用し、物（材料）の表面にこれらの合金を被膜させることもできる。このように、物の表面に合金の薄膜を形成することで、抗ウイルス性を付与することができる。 Further, the silver (Ag) -tin (Sn) -gold (Au) alloy of the present embodiment is used as a target material for thin film formation used in, for example, a sputtering method, a vacuum deposition method, and an ion plating method. The surface of the material) can also be coated with these alloys. By forming an alloy thin film on the surface of an object in this way, antiviral properties can be imparted.
以上、本実施形態について説明したが、これ以外にも、本発明の主旨を逸脱しない限り、上記実施の形態で挙げた構成を取捨選択したり、他の構成に適宜変更することが可能である。本実施形態では、抗ウイルス性について調べたが、本実施形態に係る合金は、抗菌性も有すると考えられる。
本実施形態に係る合金には、銀よりも標準電極電位が高い金（Ａｕ）を用いたが、金（Ａｕ）以外の金属として、パラジウム（Ｐｄ）、イリジウム（Ｉｒ）、白金（Ｐｔ）、ルテニウム（Ｒｕ）、ロジウム（Ｒｈ）を用いることもできる。また、本実施形態に係る合金には、錫（Ｓｎ）を用いたが、錫（Ｓｎ）以外の金属として、亜鉛（Ｚｎ）、ガリウム（Ｇａ）、アルミニウム（Ａｌ）、ビスマス（Ｂｉ）、アンチモン（Ｓｂ）、インジウム（Ｉｎ）を用いることもできる。
Although the present embodiment has been described above, other than this, the configuration described in the above embodiment can be selected or changed as appropriate without departing from the gist of the present invention. .. In this embodiment, the antiviral property has been investigated, but it is considered that the alloy according to the present embodiment also has antibacterial property.
Gold (Au), which has a higher standard electrode potential than silver, was used as the alloy according to the present embodiment, but palladium (Pd), iridium (Ir), platinum (Pt), and other metals other than gold (Au) were used. Ruthenium (Ru) and rhodium (Rh) can also be used. Further, although tin (Sn) was used as the alloy according to the present embodiment, as metals other than tin (Sn), zinc (Zn), gallium (Ga), aluminum (Al), bismuth (Bi), and antimony were used. (Sb) and indium (In) can also be used.
Claims (2)
２．５重量％から１０．０重量％の錫（Ｓｎ）と、
０．０１重量％から１．０重量％の金（Ａｕ）と、が含まれ、
残部が銀（Ａｇ）で構成される、
ことを特徴とする合金から成る抗ウイルス性部材。 An antiviral member made of an alloy having antiviral properties.
From 2.5% to 10.0% by weight of tin (Sn),
Contains 0.01% to 1.0% by weight of gold (Au),
The rest is made of silver (Ag),
An antiviral member made of an alloy.
請求項１に記載の合金から成る抗ウイルス性部材。 The tin (Sn) is contained in an amount of 3.95% by weight or more.
An antiviral member made of the alloy according to claim 1.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019165563A JP6774690B1 (en) | 2019-09-11 | 2019-09-11 | Antiviral alloy |
| PCT/JP2020/017041 WO2021049086A1 (en) | 2019-09-11 | 2020-04-20 | Antiviral alloy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019165563A JP6774690B1 (en) | 2019-09-11 | 2019-09-11 | Antiviral alloy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP6774690B1 true JP6774690B1 (en) | 2020-10-28 |
| JP2021042438A JP2021042438A (en) | 2021-03-18 |
Family
ID=72938125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019165563A Active JP6774690B1 (en) | 2019-09-11 | 2019-09-11 | Antiviral alloy |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP6774690B1 (en) |
| WO (1) | WO2021049086A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7440153B1 (en) | 2023-09-19 | 2024-02-28 | 相田化学工業株式会社 | Antiviral alloys and antiviral components |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681575A (en) * | 1992-05-19 | 1997-10-28 | Westaim Technologies Inc. | Anti-microbial coating for medical devices |
| JPH09111378A (en) * | 1995-10-18 | 1997-04-28 | Nisshin Steel Co Ltd | Ag-cu-sn alloy excellent in antibacterial and antimold property |
| JP4714477B2 (en) * | 2004-02-19 | 2011-06-29 | アルバック成膜株式会社 | Ag alloy film and manufacturing method thereof |
-
2019
- 2019-09-11 JP JP2019165563A patent/JP6774690B1/en active Active
-
2020
- 2020-04-20 WO PCT/JP2020/017041 patent/WO2021049086A1/en active Application Filing
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7440153B1 (en) | 2023-09-19 | 2024-02-28 | 相田化学工業株式会社 | Antiviral alloys and antiviral components |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021042438A (en) | 2021-03-18 |
| WO2021049086A1 (en) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5656138B1 (en) | Phosphor bronze alloy having antibacterial properties and article using the same | |
| Hans et al. | Physicochemical properties of copper important for its antibacterial activity and development of a unified model | |
| JP5806698B2 (en) | Novel antimicrobial substrate and use thereof | |
| JP4778123B2 (en) | Antimicrobial material, method for producing the same, and antimicrobial material | |
| JP6774690B1 (en) | Antiviral alloy | |
| JP4357166B2 (en) | Antibacterial / antifungal / algae-proof composition | |
| JP2019089752A (en) | Article in which antibacterial property is reduced 30% or more by applying specific coating agent to thin film sheet shaped article by roughing phosphor bronze alloy surface, glossiness is further eliminated by the coating agent compared to phosphor bronze alloy remaining roughening state and fingerprint is prevented from becoming conspicuous | |
| WO2007140173A2 (en) | Methods of maintaining and using a high concentration of dissolved copper on the surface of a useful article | |
| JP4774072B2 (en) | Antibacterial and antifungal composition and its application | |
| EP3098333A1 (en) | Electrolytic bath for producing antibacterial metal coatings containing nickel, phosphorus and nanoparticles of an antibacterial metal (ni-p-manp's) | |
| WO1998038349A1 (en) | Antibacterial hardwares and method of production thereof | |
| JP2010247450A (en) | Antibacterial film | |
| KR20170042351A (en) | Antiseptic preparation and utilization method thereof | |
| JP6439217B2 (en) | A method for producing tungsten trioxide and tungsten dioxide. | |
| JP7440153B1 (en) | Antiviral alloys and antiviral components | |
| JPH0751328A (en) | Fixtures and sanitary supplies for hospital | |
| JP6258113B2 (en) | Method for producing antibacterial titanium alloy material | |
| US11155899B2 (en) | Antimicrobial, hypoallergenic, and tarnish-resistant Cu-based alloy and related methods thereof | |
| JP3533601B2 (en) | Method for producing an article having antibacterial properties | |
| IT202000005383U1 (en) | MULTIPURPOSE ANTI BACTERIAL AND ANTIVIRAL CLEANER FOR CLEANING NON-POROUS SURFACES | |
| JP2008114138A (en) | Functional water | |
| JP2022167393A (en) | Antimicrobial plating film, and method of producing the same | |
| WO2018029732A1 (en) | Cockroach-repellent coating material | |
| TW202245604A (en) | Phosphor bronze alloy powder | |
| CN115551658A (en) | Phosphor bronze alloy powder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200311 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200311 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200324 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200721 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200826 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200915 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200928 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6774690 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |